AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3534992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortin butylester (FCB) 4 mg daily
Number of subjects: 30
Study 3534992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30649149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 0
Study 30649149 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study 29173738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 279
Study 25632203 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 66
Study 25632203 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 66
Study 25632203 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 66
Study 23527715 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg sodium hyaluronate
Number of subjects: 75
Study 23527715 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 75
Study 21720259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues program
Number of subjects: 121
Study 21720259 — intervention group
Group type: COMPARATOR
Intervention: Care (attention control)
Number of subjects: 121
Study 19491816 — intervention group
Group type: EXPERIMENTAL
Intervention: Velaxin (venlafaxine) 75 mg daily for 8 weeks
Number of subjects: 47
Study 19491816 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antidepressants or antiepileptics)
Number of subjects: 47
Study 16947783 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment (up to 25 mg per week orally) combined with folic acid
Number of subjects: 205
Study 12929065 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) using propofol and alfentanil
Number of subjects: 67
Study 12929065 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and pethidine
Number of subjects: 67
Study 10849058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon extract (40 mg twice daily for 4 weeks)
Number of subjects: 15
Study 10849058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9111403 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar replacement during total knee arthroplasty
Number of subjects: 26
Study 9111403 — intervention group
Group type: COMPARATOR
Intervention: No patellar replacement during total knee arthroplasty
Number of subjects: 26
Study 8462917 — intervention group
Group type: COMPARATOR
Intervention: Tannacomp (500 mg of tannin albuminate and 50 mg ethacridine lactate), administered as 2 tablets three times a day for 5 days, followed by 5 days without treatment, then another 5 days of the same regimen.
Number of subjects: 30
Study 3517701 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 300 mg per diem for 14 days
Number of subjects: 16
Study 3517701 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 150 mg per diem for 14 days
Number of subjects: 16
Study 3517701 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 16
Study 3517701 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 16
Study 30194992 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg weekly for 16 weeks
Number of subjects: 54
Study 30194992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 30194992 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 54
Study 29097122 — intervention group
Group type: EXPERIMENTAL
Intervention: FT+TMP gel
Number of subjects: 12
Study 29097122 — intervention group
Group type: EXPERIMENTAL
Intervention: FT+Acid gel
Number of subjects: 12
Study 29097122 — intervention group
Group type: EXPERIMENTAL
Intervention: FT+9000 gel
Number of subjects: 12
Study 29097122 — intervention group
Group type: EXPERIMENTAL
Intervention: FT
Number of subjects: 12
Study 29097122 — intervention group
Group type: COMPARATOR
Intervention: PT
Number of subjects: 12
Study 27044884 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear extrapolation (LE)
Number of subjects: 918
Study 27044884 — intervention group
Group type: EXPERIMENTAL
Intervention: Last observation carried forward (LOCF)
Number of subjects: 918
Study 23417668 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P (Positive Parenting Program)
Number of subjects: 280
Study 23417668 — intervention group
Group type: COMPARATOR
Intervention: No parenting intervention (control)
Number of subjects: 280
Study 22356267 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (Seme) 200μg daily for 3 months (Se3), n = 15
Number of subjects: 86
Study 22356267 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (Seme) 200μg daily for 6 months (Se6), n = 46
Number of subjects: 86
Study 22356267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control), n = 25
Number of subjects: 86
Study 20378225 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberative democracy sessions
Number of subjects: 0
Study 20378225 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study 17875253 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Children, Strong Families intervention promoting healthy eating and physical activity; details on dosage and duration not specified.
Number of subjects: 0
Study 15895312 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol (SAL)
Number of subjects: 8
Study 15895312 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg ipratropium bromide (IPR)
Number of subjects: 8
Study 15895312 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 11553197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal insulin (three preprandial doses combined with one evening subcutaneous NPH if needed)
Number of subjects: 10
Study 11553197 — intervention group
Group type: COMPARATOR
Intervention: NPH injections (two daily)
Number of subjects: 10
Study 11553197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal insulin
Number of subjects: 10
Study 9605365 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 28
Study 9605365 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 28
Study 7989953 — intervention group
Group type: COMPARATOR
Intervention: Single-dose NSAIDs
Number of subjects: 1545
Study 7989953 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1545
Study 7989953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low- and high-dose NSAIDs
Number of subjects: 1545
Study 7989953 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended and supramaximal single doses of three NSAIDs
Number of subjects: 1545
Study 7989953 — intervention group
Group type: COMPARATOR
Intervention: Weak opioids (WO) alone or in combination (WO/C) with nonopioid analgesics
Number of subjects: 1545
Study 7989953 — intervention group
Group type: COMPARATOR
Intervention: Single doses of WO/C analgesics
Number of subjects: 1545
Study 7989953 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of NSAIDs
Number of subjects: 1545
Study 3171371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline 1 in 200,000
Number of subjects: 18
Study 3171371 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine 3% with felypressin 0.03 international units/ml
Number of subjects: 18
Study 29794759 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrisofix Chest Orthosis (CCO)
Number of subjects: 24
Study 29794759 — intervention group
Group type: EXPERIMENTAL
Intervention: ER splint
Number of subjects: 24
Study 27145364 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-citalopram AUC(0,24 h)
Number of subjects: 0
Study 27145364 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-citalopram AUC(0,24 h)
Number of subjects: 0
Study 24724835 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzocaine
Number of subjects: 21
Study 24724835 — intervention group
Group type: COMPARATOR
Intervention: No benzocaine (control)
Number of subjects: 21
Study 22744627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 24
Study 22744627 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin administration
Number of subjects: 24
Study 20334685 — intervention group
Group type: COMPARATOR
Intervention: LBC at entry and two years, combined LBC and hr-HPV at four years among those with initial negative results and hr-HPV triage of ASCUS cases (Control Arm)
Number of subjects: 33000
Study 20334685 — intervention group
Group type: EXPERIMENTAL
Intervention: hr-HPV at entry and LBC at two years in those with initial negative results with LBC triage of hr-HPV positives (Two Year Safety Check Arm)
Number of subjects: 33000
Study 20334685 — intervention group
Group type: EXPERIMENTAL
Intervention: hr-HPV at entry and combined hr-HPV and LBC at four years among those with initial negative results with LBC triage of hr-HPV positive cases (Four Year Intervention Arm)
Number of subjects: 33000
Study 17461735 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-antiarrhythmic drugs (beta-blockers, aldosterone antagonists, ACE inhibitors, angiotensin receptor-blockers, statins, omega-3 fatty acids)
Number of subjects: 0
Study 17461735 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-antiarrhythmic drugs
Number of subjects: 0
Study 15655123 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan intervention
Number of subjects: 8206
Study 15655123 — intervention group
Group type: COMPARATOR
Intervention: Low baseline/low year 1 UACR
Number of subjects: 8206
Study 15655123 — intervention group
Group type: COMPARATOR
Intervention: Low baseline/high year 1 UACR
Number of subjects: 8206
Study 15655123 — intervention group
Group type: COMPARATOR
Intervention: High baseline/low year 1 UACR
Number of subjects: 8206
Study 15655123 — intervention group
Group type: COMPARATOR
Intervention: High baseline/high year 1 UACR
Number of subjects: 8206
Study 15655123 — intervention group
Group type: EXPERIMENTAL
Intervention: Components of primary composite endpoint (cardiovascular mortality, stroke, myocardial infarction)
Number of subjects: 8206
Study 11854676 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS Empress crowns luted with Variolink II low-viscosity resin cement and Syntac Classic dentin adhesive
Number of subjects: 20
Study 11854676 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS Empress crowns luted with Variolink II and Syntac Single Component
Number of subjects: 20
Study 11854676 — intervention group
Group type: COMPARATOR
Intervention: Crowns with subgingival margin finish lines
Number of subjects: 20
Study 10378327 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation of unspecified duration
Number of subjects: 0
Study 10378327 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal deep vein thrombosis or symptomatic pulmonary embolism
Number of subjects: 0
Study 10378327 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent or unknown triggering factor
Number of subjects: 0
Study 10378327 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of proximal deep vein thrombosis or symptomatic pulmonary embolism and permanent/unknown triggering factor
Number of subjects: 0
Study 10378327 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cardiolipin antibodies
Number of subjects: 0
Study 8891761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 10
Study 8891761 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 10
Study 8891761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2066757 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate adjuvant chemotherapy
Number of subjects: 113
Study 2066757 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 113
Study 2066757 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and adjuvant chemotherapy
Number of subjects: 113
Study 2066757 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical disease-free after initial relapse
Number of subjects: 113
Study 6133575 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal desensitization
Number of subjects: 20
Study 6133575 — intervention group
Group type: COMPARATOR
Intervention: Aversion-relief therapy
Number of subjects: 20
Study 31347669 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets with varying nutrient compositions (16 diets)
Number of subjects: 48
Study 31347669 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation experiment with 2 diets
Number of subjects: 48
Study 30113559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential bilateral cochlear implantation with a 2‐year interimplant interval
Number of subjects: 16
Study 26955768 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine administration during rapid sequence induction (RSI) for general anesthesia
Number of subjects: 30
Study 25088394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU per day)
Number of subjects: 247
Study 25088394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 22248711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (single subcutaneous injection at day 5)
Number of subjects: 151
Study 22248711 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (daily injections from day 5 until recovery of ANC to 0.5 G/L)
Number of subjects: 151
Study 19439949 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dentifrice (1,100 microg F/g)
Number of subjects: 0
Study 19439949 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-F dentifrice (500 microg F/g)
Number of subjects: 0
Study 19439949 — intervention group
Group type: COMPARATOR
Intervention: Non-F dentifrice (negative control)
Number of subjects: 0
Study 17617747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 mg bid
Number of subjects: 363
Study 17617747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 750 mg or 1000 mg bid
Number of subjects: 363
Study 17617747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 16172458 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 355
Study 16172458 — intervention group
Group type: COMPARATOR
Intervention: Stanford V
Number of subjects: 355
Study 16172458 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPPEBVCAD
Number of subjects: 355
Study 11205198 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5 FU) alone (arm A: 450 mg/m2/day‐5/21 days)
Number of subjects: 366
Study 11205198 — intervention group
Group type: COMPARATOR
Intervention: Combined folinic acid (FOL) and 5 FU (arm B: 200 mg/m2 racemic form or 100 mg/m2‐l‐form and 370 mg/m2/day‐5/21 days)
Number of subjects: 366
Study 11205198 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 FU alone (arm A)
Number of subjects: 366
Study 11205198 — intervention group
Group type: COMPARATOR
Intervention: Combined FOL and 5 FU (arm B)
Number of subjects: 366
Study 9315984 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (200 mg a.m. and 100 mg p.m.)
Number of subjects: 60
Study 9315984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9315984 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 60
Study 8417635 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallstone disease
Number of subjects: 383
Study 8417635 — intervention group
Group type: COMPARATOR
Intervention: Normal gallbladders
Number of subjects: 383
Study 3948628 — intervention group
Group type: EXPERIMENTAL
Intervention: Octylonium bromide (80 mg, qid, per os) for 5-7 days
Number of subjects: 20
Study 3948628 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 20
Study 3948628 — intervention group
Group type: COMPARATOR
Intervention: IBS patients (without treatment)
Number of subjects: 20
Study 3948628 — intervention group
Group type: COMPARATOR
Intervention: Gastric emptying
Number of subjects: 20
Study 3365885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty
Number of subjects: 34
Study 3365885 — intervention group
Group type: COMPARATOR
Intervention: Open reduction
Number of subjects: 34
Study 31132664 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg/mL three times weekly (GA40)
Number of subjects: 861
Study 31132664 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate 20 mg/mL once daily (GA20)
Number of subjects: 861
Study 28976536 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening (FS) at baseline and at 3 or 5 years
Number of subjects: 154900
Study 28976536 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154900
Study 26160608 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg/day
Number of subjects: 79
Study 26160608 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 79
Study 23218817 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% gel
Number of subjects: 406
Study 23218817 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 406
Study 21253774 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (individually adapted supplements enriched with protein and antioxidants)
Number of subjects: 23
Study 21253774 — intervention group
Group type: COMPARATOR
Intervention: Control (unsupplemented)
Number of subjects: 23
Study 21253774 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 23
Study 21253774 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplementation and Control
Number of subjects: 23
Study 18460217 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' Evaluation of Developmental Status (PEDS) screening
Number of subjects: 791
Study 18460217 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for assessment
Number of subjects: 791
Study 18460217 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for delay
Number of subjects: 791
Study 18460217 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted probability of high risk screening
Number of subjects: 791
Study 16507859 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 81 mg once daily
Number of subjects: 19
Study 16507859 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 19
Study 16507859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12735583 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (5 mL delivered by aerosolized spraying)
Number of subjects: 100
Study 12735583 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 100
Study 11054621 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (long-term treatment, 4 months)
Number of subjects: 29
Study 11054621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11054621 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (long-term treatment)
Number of subjects: 29
Study 9076868 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 400 mg T.I.D. for 48 hours
Number of subjects: 6
Study 9076868 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin higher doses (up to 3600 mg/day) during open-label extension
Number of subjects: 6
Study 9076868 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg T.I.D. and 800 mg T.I.D.
Number of subjects: 6
Study 9076868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8398955 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-gauge Sprotte needle
Number of subjects: 194
Study 8398955 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke needle
Number of subjects: 194
Study 8398955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprotte with fentanyl (n = 47)
Number of subjects: 194
Study 8398955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprotte without fentanyl (n = 49)
Number of subjects: 194
Study 8398955 — intervention group
Group type: EXPERIMENTAL
Intervention: Quincke with fentanyl (n = 49)
Number of subjects: 194
Study 8398955 — intervention group
Group type: EXPERIMENTAL
Intervention: Quincke without fentanyl (n = 49)
Number of subjects: 194
Study 8398955 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blood patch therapy
Number of subjects: 194
Study 8398955 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl as adjunct
Number of subjects: 194
Study 3533203 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion (at least 2 units within 24 hours after admission)
Number of subjects: 75
Study 3533203 — intervention group
Group type: COMPARATOR
Intervention: No blood transfusion unless hemoglobin fell below 8 g/dl or patients were shocked (control group)
Number of subjects: 75
Study 31359832 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 1207
Study 31359832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study 28071330 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon β‐1a
Number of subjects: 37
Study 28071330 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education about ISR potential
Number of subjects: 37
Study 26270625 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 IU kg(‐1) PCC
Number of subjects: 6
Study 26270625 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 IU kg(‐1) PCC
Number of subjects: 6
Study 26270625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 23686969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive–behavioral therapy
Number of subjects: 114
Study 21458721 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (major ablative and reconstructive procedures)
Number of subjects: 5
Study 21458721 — intervention group
Group type: COMPARATOR
Intervention: Resting testosterone levels
Number of subjects: 5
Study 18486703 — intervention group
Group type: EXPERIMENTAL
Intervention: Burr hole drainage with irrigation
Number of subjects: 82
Study 18486703 — intervention group
Group type: COMPARATOR
Intervention: Burr hole drainage without irrigation
Number of subjects: 82
Study 17144124 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (usual doses)
Number of subjects: 126